NYSE · Drug Manufacturers - Specialty & Generic
Perrigo Company plc (PRGO) Stock
$14.50
-0.34%
NYSE: PRGO
Healthcare
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Perrigo Announces Appointment of Two New Independent Directors to Board
PR Newswire · Jun 30, 2026
Stryker (SYK) Moves 5.3% Higher: Will This Strength Last?
Zacks · Jun 29, 2026
FDA Seeks Updated Labeling for Testosterone Therapies
MT Newswires · Jun 18, 2026
Jim Cramer on Perrigo Comapny: “This Is a Value Trap”
Insider Monkey · Jun 17, 2026
Perrigo Leadership Shakeup Puts Governance And Long Term Strategy In Focus
Simply Wall St. · Jun 9, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held0.40%
Institutions Held116.80%
Institutions Float Held117.27%
Peer Comparison
About Perrigo Company plc
Perrigo Company plc is led by CEO Patrick Lockwood-Taylor, publicly traded since 1991.
Perrigo Company plc (PRGO) stock trades at $14.50 with a market capitalization of $2.01B. The stock is valued at a price-to-earnings (P/E) ratio of -1.14, price-to-book of 0.79, price-to-sales of 0.48. Over the past 52 weeks the stock has ranged between $9.23 and $22.48, and currently trades 35.5% below its 52-week high. It pays a dividend yielding 8.13%.
On profitability, Perrigo Company plc generates a return on equity (ROE) of -55.97%, return on capital employed of 3.28%, an operating margin of 8.06%, a net profit margin of -41.85%.